<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03640312</url>
  </required_header>
  <id_info>
    <org_study_id>STU00205834</org_study_id>
    <nct_id>NCT03640312</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of a Quadruple Ultra-low-dose Treatment for Hypertension</brief_title>
  <acronym>QUARTET USA</acronym>
  <official_title>A Double Blind Randomized Controlled Trial to Assess the Efficacy and Safety of a Quadruple Ultra-low-dose Treatment for Hypertension (QUARTET USA)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Northwestern University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ACCESS Community Health Network</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Sydney</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Northwestern University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate, in a double-blind randomized controlled trial, whether initiating treatment&#xD;
      with ultra-low-dose quadruple-combination therapy (&quot;LDQT&quot;) will lower office blood pressure&#xD;
      more effectively, and with fewer side effects, compared to initiating standard dose&#xD;
      monotherapy as per current guidelines in patients with hypertension.&#xD;
&#xD;
      Primary hypothesis: A combination pill comprising four types of blood pressure lowering&#xD;
      medications, each at one-quarter standard doses, will lower office blood pressure more&#xD;
      effectively than initiating patients with standard dose monotherapy as per contemporary&#xD;
      clinical practice guideline recommendations.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This trial will investigate whether initiating treatment with ultra-low-dose&#xD;
      quadruple-combination therapy (LDQT; including candesartan 2 mg, amlodipine 1.25 mg,&#xD;
      indapamide 0.625 mg, and bisoprolol 2.5 mg) will lower automated office blood pressure and&#xD;
      24-hour ambulatory blood pressure at 12 weeks more effectively, and with no increase in side&#xD;
      effects, compared to initiating standard dose monotherapy (candesartan 8 mg) in adults with&#xD;
      raised blood pressure (SBP&gt;130 mmHg or DBP&gt;80 mmHg) and without cardiovascular disease. Our&#xD;
      preliminary data from a short-term (4-week) crossover trial of 18 participants suggest that&#xD;
      LDQT lowers office blood pressure by 22/13 mmHg on average compared with placebo with no&#xD;
      difference in serious adverse events. Effects on 24-hour ambulatory blood pressure were&#xD;
      similar.&#xD;
&#xD;
      The investigators will perform this phase II, single site, randomized controlled trial in a&#xD;
      network of federally qualified health centers in Chicago because this population bears a&#xD;
      disproportionate burden of blood pressure related diseases, and the investigators have&#xD;
      previously successfully conducted clinical studies in this population.&#xD;
&#xD;
      While the investigators hypothesize this intervention will be easily implemented and&#xD;
      efficacious for all patients and clinicians, the investigators will explore variation in&#xD;
      treatment effect by potential moderating variables, including age, sex, race/ethnicity, and&#xD;
      health literacy level. Beyond examining efficacy, the investigators also plan to assess&#xD;
      feasibility of implementing this intervention in a clinical setting by simultaneously&#xD;
      evaluating implementation outcomes of acceptability, preferences, and lessons of LDQT among&#xD;
      patients and clinicians.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 30, 2019</start_date>
  <completion_date type="Anticipated">March 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Mean Systolic Blood Pressure</measure>
    <time_frame>12 weeks</time_frame>
    <description>Mean change (from baseline) in automated office systolic blood pressure adjusted for baseline values.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Systolic Blood Pressure</measure>
    <time_frame>6 weeks</time_frame>
    <description>Mean automated office systolic blood pressure adjusted for baseline values.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Mean Diastolic Blood Pressure</measure>
    <time_frame>6 and 12 weeks</time_frame>
    <description>Mean change (from baseline) in automated office diastolic blood pressure adjusted for baseline values.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Diastolic Blood Pressure</measure>
    <time_frame>6 and 12 weeks</time_frame>
    <description>Mean automated office diastolic blood pressure adjusted for baseline values.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with hypertension control</measure>
    <time_frame>6 and 12 weeks</time_frame>
    <description>Proportion of patients with hypertension control (percent with SBP &lt; 130 mmHg and DBP &lt;80 mmHg).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients requiring step up treatment</measure>
    <time_frame>6 and 12 weeks</time_frame>
    <description>Proportion of patients requiring step-up treatment (ever, and at each study time point).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with adverse event free hypertension control</measure>
    <time_frame>12 weeks</time_frame>
    <description>Proportion of patients with adverse event free hypertension control (percent with SBP &lt; 130 mmHg and DBP &lt;80 mmHg).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Medication Adherence</measure>
    <time_frame>6 and 12 weeks</time_frame>
    <description>Medication adherence defined by objective pill counts</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health-related quality of life</measure>
    <time_frame>12 weeks</time_frame>
    <description>Mean change (from baseline) in health-related quality of life using PROMIS Global Health instrument.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Mean Systolic Blood Pressure</measure>
    <time_frame>6 weeks</time_frame>
    <description>Mean change (from baseline) in automated office systolic blood pressure adjusted for baseline values.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Percentage of Participants with Severe adverse events</measure>
    <time_frame>12 weeks</time_frame>
    <description>Percentage of participants with any severe adverse event (SAE) according to Good Clinical Practice definition.</description>
  </other_outcome>
  <other_outcome>
    <measure>Percentage of Participants with Side effects</measure>
    <time_frame>12 weeks</time_frame>
    <description>Percentage of participants with occurrence of any potentially relevant side effect (pre-specified as in study procedures).</description>
  </other_outcome>
  <other_outcome>
    <measure>Rate of relevant side effects</measure>
    <time_frame>12 weeks</time_frame>
    <description>Rate of relevant side effects (pre-specified as in study procedures) at the participant level.</description>
  </other_outcome>
  <other_outcome>
    <measure>Mean Change in Serum Potassium</measure>
    <time_frame>12 weeks</time_frame>
    <description>Mean change (from baseline) in continuous serum potassium.</description>
  </other_outcome>
  <other_outcome>
    <measure>Mean Change in Serum Sodium</measure>
    <time_frame>12 weeks</time_frame>
    <description>Mean change (from baseline) in continuous serum sodium.</description>
  </other_outcome>
  <other_outcome>
    <measure>Mean Change in Blood Urea Nitrogen</measure>
    <time_frame>12 weeks</time_frame>
    <description>Mean change (from baseline) in continuous blood urea nitrogen.</description>
  </other_outcome>
  <other_outcome>
    <measure>Mean Change in Serum Creatinine</measure>
    <time_frame>12 weeks</time_frame>
    <description>Mean change in continuous serum creatinine.</description>
  </other_outcome>
  <other_outcome>
    <measure>Mean Daytime Blood Pressure Load</measure>
    <time_frame>24 hours at 12 week follow up</time_frame>
    <description>Mean daytime blood pressure load assessed through 24-hour ambulatory blood pressure (ABPM).</description>
  </other_outcome>
  <other_outcome>
    <measure>Mean Nightime Blood Pressure Load</measure>
    <time_frame>24 hours at 12 week follow up</time_frame>
    <description>Mean nighttime blood pressure load assessed through 24-hour ambulatory blood pressure.</description>
  </other_outcome>
  <other_outcome>
    <measure>Percentage of Participants with Morning Surge</measure>
    <time_frame>24 hours at 12 week follow up</time_frame>
    <description>Percentage of participants with morning surge, calculated as the difference between the mean SBP during the morning hours and nighttime trough SBP, assessed through 24-hour ambulatory blood pressure.</description>
  </other_outcome>
  <other_outcome>
    <measure>Coefficient of Variability of Blood Pressure</measure>
    <time_frame>24 hours at 12 week follow up</time_frame>
    <description>Coefficient of variability of blood pressure, defined as the ratio of the 24-hour standard deviation of BP / mean 24-hour value, assessed through 24-hour ambulatory blood pressure.</description>
  </other_outcome>
  <other_outcome>
    <measure>Day-night Blood Pressure Variability</measure>
    <time_frame>24 hours at 12 week follow up</time_frame>
    <description>Day-night variability (SDdn), which uses the SD for daytime measurements and, separately for nighttime measurements, to calculate a weighted mean of these SDs, assessed through 24-hour ambulatory blood pressure.</description>
  </other_outcome>
  <other_outcome>
    <measure>Average Real Blood Pressure Variability</measure>
    <time_frame>24 hours at 12 week follow up</time_frame>
    <description>Average real variability (ARV), calculated as the average absolute difference between consecutive readings over the 24-hour ABPM period, assessed through 24-hour ambulatory blood pressure.</description>
  </other_outcome>
  <other_outcome>
    <measure>Mean Systolic Blood Pressure</measure>
    <time_frame>12 weeks</time_frame>
    <description>Mean automated office systolic blood pressure adjusted for baseline values.</description>
  </other_outcome>
  <other_outcome>
    <measure>Mean 24-Hour Blood Pressure</measure>
    <time_frame>24 hours at 12 week follow up</time_frame>
    <description>Mean 24-hour systolic and diastolic blood pressure assessed through 24-hour ambulatory blood pressure adjusted for baseline values.</description>
  </other_outcome>
  <other_outcome>
    <measure>Mean Daytime Blood Pressure</measure>
    <time_frame>24 hours at 12 week follow up</time_frame>
    <description>Mean daytime (0600 to 2200) systolic and diastolic blood pressure assessed through 24-hour ambulatory blood pressure adjusted for baseline values.</description>
  </other_outcome>
  <other_outcome>
    <measure>Mean Nighttime Blood Pressure</measure>
    <time_frame>24 hours at 12 week follow up</time_frame>
    <description>Mean daytime (2200 to 0600) systolic and diastolic blood pressure assessed through 24-hour ambulatory blood pressure adjusted for baseline values.</description>
  </other_outcome>
  <other_outcome>
    <measure>Proportion of dippers</measure>
    <time_frame>24 hours at 12 week follow up</time_frame>
    <description>Proportion of dippers assessed through 24-hour ambulatory blood pressure adjusted for baseline values.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">87</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>QUARTET LDQT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients randomized to the intervention arm will take a once daily ultra-low-dose quadruple combination therapy (QUARTET LDQT). The LDQT is an overencapsulated combination pill comprising four types of blood pressure lowering medications each at ¼ standard doses. QUARTET includes candesartan 2mg, amlodipine besylate 1.25mg, indapamide 0.625mg, and bisoprolol 2.5mg. The individual components are currently approved and marketed within the United States.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Candesartan</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients randomized to the comparison arm will take a once daily 8mg candesartan.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>QUARTET LDQT</intervention_name>
    <description>Ultra-low-dose combination therapy comprising four different blood pressure lowering drugs at 1/4 dosages. Taken once daily for 12 weeks.</description>
    <arm_group_label>QUARTET LDQT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Candesartan</intervention_name>
    <description>Standard monotherapy of 8mg candesartan. Taken once daily for 12 weeks.</description>
    <arm_group_label>Candesartan</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adults (≥18 years)&#xD;
&#xD;
          -  Spanish or English speaker.&#xD;
&#xD;
          -  Previous documentation within the past 24 months of hypertension or high blood&#xD;
             pressure (SBP 130-179 mmHg or DBP 80-109 mmHg) from general practitioner, pharmacist&#xD;
             or health care professional (e.g., medical assistant, physician or nurse).&#xD;
&#xD;
          -  Either: 1) Untreated (automated) clinic SBP 140-179 or DBP 90-109 mmHg in the last 12&#xD;
             weeks, OR 2) Monotherapy with clinic SBP 130-159 or DBP 85-99 mmHg in the last 12&#xD;
             weeks.&#xD;
&#xD;
          -  Either: 1) Treatment naïve, OR 2) Currently not on treatment (not take in last 4&#xD;
             weeks), OR 3) Currently taking 1 BP lowering drug (ACE, ARB, CCB, thiazide- or&#xD;
             thiazide-like diuretic, BB, MRA, alpha blocker) at any dose.&#xD;
&#xD;
          -  Research grade blood pressure measurement (baseline mean) SBP&gt;= 115 mmHg and DBP &gt;= 60&#xD;
             mmHg&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known contraindication to candesartan, amlodipine, indapamide or bisoprolol.&#xD;
&#xD;
          -  Previous diagnosis of coronary artery disease, stroke, or heart failure.&#xD;
&#xD;
          -  Presence of significant proteinuria (based on 3+ proteinuria via spot urinalysis or&#xD;
             &gt;300mg/dL of proteinuria based on random urinary albumin-to-creatinine ratio testing&#xD;
             of 300 mg/g)&#xD;
&#xD;
          -  Evidence of secondary cause of hypertension e.g., renal artery stenosis; significant&#xD;
             renal impairment (eGFR &lt;50 ml/min/1.73 m2), raised serum potassium (above lab normal&#xD;
             limit of 5.5 mEq/L).&#xD;
&#xD;
          -  Women who are pregnant, breast feeding or of childbearing potential and are not using&#xD;
             and do not plan to continue using medically acceptable form of contraception&#xD;
             throughout the study (pharmacological or barrier methods).&#xD;
&#xD;
          -  Concomitant illness, physical impairment or mental condition which in the opinion of&#xD;
             the study team / primary care physician could interfere with the conduct of the study&#xD;
             including outcome assessments.&#xD;
&#xD;
          -  Participation in a concurrent interventional medical investigation or pharmacologic&#xD;
             clinical trial. Patients in observational, natural history or epidemiological studies&#xD;
             not involving an intervention are eligible.&#xD;
&#xD;
          -  Participant's responsible primary care or other responsible physician believes it is&#xD;
             not appropriate for participant to switch current monotherapy.&#xD;
&#xD;
          -  Inability or unwillingness to provide written informed consent.&#xD;
&#xD;
          -  Unable to complete study procedures.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark D Huffman, PhD, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Northwestern University Feinberg School of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jody D Ciolino, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Overall Study Officials:</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Abigail S Baldridge, MS</last_name>
    <phone>3125033911</phone>
    <email>abigail.baldridge@northwestern.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>ACCESS Martin T. Russo Family Health Center</name>
      <address>
        <city>Bloomingdale</city>
        <state>Illinois</state>
        <zip>60108</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hiba Abbas, RN</last_name>
      <phone>872-772-0389</phone>
      <email>hiba.abbas@achn.net</email>
    </contact>
    <investigator>
      <last_name>Jairo A Mejia, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Charity Alikpala, DO</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ashland Family Health Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60609</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fallon Flowers, RN</last_name>
      <phone>872-772-0423</phone>
      <email>fallon.flowers@achn.net</email>
    </contact>
    <investigator>
      <last_name>Daneen Woodard, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>August 15, 2018</study_first_submitted>
  <study_first_submitted_qc>August 17, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 21, 2018</study_first_posted>
  <last_update_submitted>September 23, 2021</last_update_submitted>
  <last_update_submitted_qc>September 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Northwestern University</investigator_affiliation>
    <investigator_full_name>Mark Huffman</investigator_full_name>
    <investigator_title>Director, Institute for Global Health - Center for Global Cardiovascular Health</investigator_title>
  </responsible_party>
  <keyword>Hypertension</keyword>
  <keyword>Blood Pressure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Candesartan</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Individual participant data will be shared through NHLBI BioLINCC.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>Data will be available within 1 year of study conclusion.</ipd_time_frame>
    <ipd_access_criteria>Access to study data will be managed through NHLBI BioLINCC</ipd_access_criteria>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>July 21, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/12/NCT03640312/ICF_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

